Summit Therapeutics (SMMT) is back in focus after the FDA issued a Complete Response Letter for ivonescimab in lung cancer, questioning overall survival evidence and the treatment’s benefit risk profile.
The regulatory setback has hit Summit Therapeutics hard, with the 7-day share price return down about 30% and the 30-day share price return down roughly 34%. The 1-year total shareholder return is lower by about 36%, but the 3-year total shareholder return remains very large, suggesting that long-term holders are coming off a strong run even as short-term momentum fades.
Capitalize on the volatility around Summit Therapeutics by scanning for other biopharma names facing similar regulatory inflection points using the hand-picked 36 healthcare AI stocks.Summit Therapeutics now trades at a steep discount to analyst targets after the FDA pushback, which leaves a blunt question hanging: Is the market prudently pricing regulatory risk or overshooting on fear as we compare price to fair value estimates next?
Against the last close of $10.57, the analyst consensus Narrative on Simply Wall St anchors Summit Therapeutics at a fair value of about $29.41, implying a wide valuation gap that only really makes sense if long term trial and regulatory risks are fully priced in.
The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types. This is most relevant for potential future revenue growth.
See why 8 investors see Summit Therapeutics as 64% undervalued.
That fair value estimate is built using a discount rate of 7.66%, very large modeled revenue growth off a zero revenue base, and a slim 4.65% profit margin assumption. Together these inputs imply a future P/E multiple of about 508x earnings if the 2029 earnings forecast of $70.8 million is reached.
Analysts also expect shares on issue to increase by roughly 7% per year over the next 3 years, and the Narrative flags that there is a wide spread between the most optimistic and most cautious earnings forecasts, so readers need to judge whether such growth, profitability and multiple expansion assumptions feel realistic for Summit Therapeutics after the recent FDA Complete Response Letter.
Result: Fair Value of $29.41 (UNDERVALUED)
Still, the entire Summit Therapeutics story hinges on ivonescimab trial and regulatory outcomes, and any setback there or sustained heavy cash burn could quickly puncture the current undervaluation narrative.
Find out about the key risks to this Summit Therapeutics narrative.
Those rich cash flow based estimates for Summit Therapeutics sit awkwardly beside what current trading multiples are saying. On a price-to-book (P/B) ratio of about 15x, the stock is described as expensive versus both the US Biotechs industry at 1.6x and a peer average of 6.7x, which raises the risk that expectations are already stretched.
That kind of gap can matter in practice. If sentiment shifts toward industry or peer-style valuations, the adjustment would fall on the share price rather than on book value, so it is worth asking how comfortable you are with paying such a premium while key trials and regulatory decisions are still in play.
See what the numbers say about this price — find out in our valuation breakdown.
Sentiment around Summit Therapeutics is clearly split, so move quickly, look through the full data set yourself, and weigh up both sides of the story by checking the 2 key rewards and 2 important warning signs.
Do not stop with Summit Therapeutics. Use this setback as a prompt to refresh your watchlist and look for stronger setups across the market.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com